The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase
- PMID:14708972
- DOI: 10.1080/07853890310018458
The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase
Abstract
It is well documented that disturbances in mitochondrial function are associated with rare childhood disorders and possibly with many common diseases of ageing, such as Parkinson's disease and dementia. There has also been increasing evidence linking mitochondrial dysfunction with tumorigenesis. Recently, heterozygous germline mutations in two enzymes of the Krebs tricarboxylic acid cycle (TCA cycle) have been shown to predispose individuals to tumours. The two enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDH), are ubiquitously expressed, playing a vital role in adenosine triphosphate (ATP) production through the mitochondrial respiratory chain. Germline mutations in FH are associated with leiomyomatosis and renal cell carcinoma, whilst SDH mutations are associated with predisposition to paraganglioma (PGL) and phaeochromocytoma (PCC). At present, there are few data to explain the pathway(s) involved in this predisposition to neoplasia through TCA cycle defects. We shall review the mechanisms by which mutations in FH and SDH might play a role in tumorigenesis. These include pseudo-hypoxia, mitochondrial dysfunction and impaired apoptosis, oxidative stress and anabolic drive. All of these mechanisms are currently poorly defined. To date, FH and SDH mutations have not been reported in non-familial leiomyomata, renal cancers, PCCs or PGLs. It remains entirely possible, however, that the underlying mechanisms of tumorigenesis in these sporadic tumours are the same as those in the Mendelian syndromes.
Similar articles
- Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP.Pollard PJ, et al.Hum Mol Genet. 2005 Aug 1;14(15):2231-9. doi: 10.1093/hmg/ddi227. Epub 2005 Jun 29.Hum Mol Genet. 2005.PMID:15987702
- Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?Laurenti G, Tennant DA.Laurenti G, et al.Biochem Soc Trans. 2016 Aug 15;44(4):1111-6. doi: 10.1042/BST20160099.Biochem Soc Trans. 2016.PMID:27528759Review.
- Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability.Lehtonen HJ, Mäkinen MJ, Kiuru M, Laiho P, Herva R, van Minderhout I, Hogendoorn PC, Cornelisse C, Devilee P, Launonen V, Aaltonen LA.Lehtonen HJ, et al.Int J Cancer. 2007 Sep 15;121(6):1386-9. doi: 10.1002/ijc.22819.Int J Cancer. 2007.PMID:17520677
- Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.Hoekstra AS, de Graaff MA, Briaire-de Bruijn IH, Ras C, Seifar RM, van Minderhout I, Cornelisse CJ, Hogendoorn PC, Breuning MH, Suijker J, Korpershoek E, Kunst HP, Frizzell N, Devilee P, Bayley JP, Bovée JV.Hoekstra AS, et al.Oncotarget. 2015 Nov 17;6(36):38777-88. doi: 10.18632/oncotarget.6091.Oncotarget. 2015.PMID:26472283Free PMC article.
- Revisiting the TCA cycle: signaling to tumor formation.Raimundo N, Baysal BE, Shadel GS.Raimundo N, et al.Trends Mol Med. 2011 Nov;17(11):641-9. doi: 10.1016/j.molmed.2011.06.001. Epub 2011 Jul 20.Trends Mol Med. 2011.PMID:21764377Free PMC article.Review.
Cited by
- What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.Losman JA, Kaelin WG Jr.Losman JA, et al.Genes Dev. 2013 Apr 15;27(8):836-52. doi: 10.1101/gad.217406.113.Genes Dev. 2013.PMID:23630074Free PMC article.Review.
- Human Metabolic Enzymes Deficiency: A Genetic Mutation Based Approach.Chaturvedi S, Singh AK, Keshari AK, Maity S, Sarkar S, Saha S.Chaturvedi S, et al.Scientifica (Cairo). 2016;2016:9828672. doi: 10.1155/2016/9828672. Epub 2016 Mar 9.Scientifica (Cairo). 2016.PMID:27051561Free PMC article.Review.
- Targeting the Metabolic Paradigms in Cancer and Diabetes.Bosso M, Haddad D, Al Madhoun A, Al-Mulla F.Bosso M, et al.Biomedicines. 2024 Jan 17;12(1):211. doi: 10.3390/biomedicines12010211.Biomedicines. 2024.PMID:38255314Free PMC article.Review.
- Novel therapeutic targets of tumor metabolism.Kishton RJ, Rathmell JC.Kishton RJ, et al.Cancer J. 2015 Mar-Apr;21(2):62-9. doi: 10.1097/PPO.0000000000000099.Cancer J. 2015.PMID:25815845Free PMC article.Review.
- MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer.Hamidi AA, Taghehchian N, Basirat Z, Zangouei AS, Moghbeli M.Hamidi AA, et al.Biomark Res. 2022 Jun 4;10(1):40. doi: 10.1186/s40364-022-00382-4.Biomark Res. 2022.PMID:35659780Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous